According to haplotype association studies, the prevalence of<unk>  in the general white population is estimated to be 1:500 to 1:1000, but in people with a high rate of marriage between relatives, the prevalence rate is as high as 1:50 to 1:100. A 2017 CYP21A2 genotype analysis predicted that the total frequency of<unk>  in the white population of the United States is about 1:200 (95% confidence level, from 1:100 to 1:280). According to a 2017 meta-analysis, the prevalence of<unk>  among women with signs and symptoms of androgen excess is 4.2% globally, and between 1% and 10% depending on the ethnicity of the population being studied.<unk> -affected individuals account for 88% of Anne Fausto-Sterling's 1.7% prevalence estimate of intersex conditions, which is cited by a number of prominent intersex advocacy organizations. From the clinical perspective,<unk>  is not an intersex condition and including<unk>  in intersex prevalence estimates has been cited as an example of dubious statistical practice.
Late onset congenital adrenal hyperplasia
Lipoid congenital adrenal hyperplasia
Congenital adrenal hyperplasia
Primary pigmented nodular adrenocortical disease
Multiple endocrine neoplasia type 1
Multiple endocrine neoplasia type 2
Multiple endocrine neoplasia
Persistent adrenarche syndrome